A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Nevirapine

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class · 7 generic manufacturers · 11 ANDAs filed at FDA.

First FDA approval2012-05-22
Generic availableYes · 7 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$2.4M in CY2024 Part D spend17K claims · 3K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.144/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.635
Across all dosage forms in distribution.
Highest NADAC
$1.37
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Nevirapine used for?

Nevirapine is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Nevirapine?

Yes. 11 ANDAs filed at FDA, 7 generic manufacturers currently shipping.

How much does my plan pay for Nevirapine?

Across 329 Part D plans, Nevirapine averages $0.635/unit (NADAC). Lowest available: $0.144/unit. Highest in distribution: $1.37/unit.

Is Nevirapine on the FDA shortage list?

No. Nevirapine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor6 alternatives in D1
01
Doravirine
Brand: PIFELTRO
$60.95Lowest NADAC
0Generic mfrs
$121.3MCY24 Part D spend
Compare →
02
Doravirine, Lamivudine, and Tenofovir Disoproxil
Brand: DELSTRIGO
$92.91Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Efavirenz
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$1.37Lowest NADAC
5Generic mfrs
$5.8MCY24 Part D spend
Compare →
04
Efavirenz, Emtricitabine and Tenofovir Disoproxil
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$1.31Lowest NADAC
6Generic mfrs
CY24 Part D spend
Compare →
05
Efavirenz, Lamivudine and Tenofovir Disoproxil
Brand: SYMFI
Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →
06
Etravirine
Brand: Intelence
$7.77Lowest NADAC
3Generic mfrs
$35.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.